165 related articles for article (PubMed ID: 26050156)
21. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
22. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
23. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
24. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin.
Choi JS; Kang KW
Arch Pharm Res; 2008 Dec; 31(12):1631-6. PubMed ID: 19099234
[TBL] [Abstract][Full Text] [Related]
25. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
26. Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.
Overby CL; Devine EB; Tarczy-Hornoch P; Kalet IJ
J Am Med Inform Assoc; 2012; 19(5):840-50. PubMed ID: 22539082
[TBL] [Abstract][Full Text] [Related]
27. Circadian variation of Valproic acid pharmacokinetics in mice.
Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
[TBL] [Abstract][Full Text] [Related]
28. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
[TBL] [Abstract][Full Text] [Related]
29. Age-related difference in tamoxifen disposition.
Peyrade F; Frenay M; Etienne MC; Ruch F; Guillemare C; François E; Namer M; Ferrero JM; Milano G
Clin Pharmacol Ther; 1996 Apr; 59(4):401-10. PubMed ID: 8612384
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
31. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
32. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic drug interactions between ondansetron and tamoxifen in female Sprague-Dawley rats with DMBA-induced mammary tumor.
Yang SH; Suh JH; Lee MG; Kim SH
Anticancer Res; 2013 Feb; 33(2):521-8. PubMed ID: 23393344
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
35. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
Li C; Kim M; Choi H; Choi J
Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator.
DeGregorio MW; Wurz GT; Taras TL; Erkkola RU; Halonen KH; Huupponen RK
Eur J Clin Pharmacol; 2000 Sep; 56(6-7):469-75. PubMed ID: 11049009
[TBL] [Abstract][Full Text] [Related]
37. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.
Jager NG; Rosing H; Schellens JH; Beijnen JH; Linn SC
Breast Cancer Res Treat; 2014 Jul; 146(1):137-44. PubMed ID: 24859000
[TBL] [Abstract][Full Text] [Related]
38. Influence of morning or evening administration on absorption of theophylline.
Su YM; Cheng TP; Yeh TW; Wen CY; Wang DI
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):113-8. PubMed ID: 10677921
[TBL] [Abstract][Full Text] [Related]
39. Study on circadian variation in folate pharmacokinetics.
Ahn E; Kapur B; Koren G
Can J Clin Pharmacol; 2005; 12(1):e4-9. PubMed ID: 15650277
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of endocrine therapy for breast cancer.
Higgins MJ; Stearns V
Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
